Preclinical Evaluation of the Pan-FGFR Inhibitor LY2874455 in FRS2-Amplified Liposarcoma
<b>Background:</b> FGFR inhibition has been proposed as treatment for dedifferentiated liposarcoma (DDLPS) with amplified <i>FRS2</i>, but we previously only demonstrated transient cytostatic effects when treating <i>FRS2</i>-amplified DDLPS cells with NVP-BGJ398....
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2019-02-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/8/2/189 |